Chandrasekaran Karthikeyan, Lee Chae Eun, Yun Seojeong, Jangid Ashok Kumar, Kim Sungjun, Kim Kyobum
Department of Chemical & Biochemical Engineering, Dongguk University, Seoul 04620, Republic of Korea.
Materials (Basel). 2025 May 6;18(9):2139. doi: 10.3390/ma18092139.
The field of cancer therapy is actively pursuing highly effective self-targeted drug delivery materials endowed with exceptional properties. Recently, hyaluronic acid (HA), a naturally occurring polysaccharide, has been recognized as a potential target ligand for CD44 receptors, which are frequently expressed on various solid tumor cells targeted in cancer therapy. HA carbon quantum dots (CQDs) exhibit several advantageous properties, including a high surface area-to-volume ratio, small particle size, biocompatibility, and low cytotoxicity, making them ideal for biomedical applications, such as CD44-targeted drug delivery in ferroptosis-based cancer therapy. In this study, we synthesized HA-CQDs to enhance CD44-mediated ligand-receptor interactions targeting triple-negative breast cancer (TNBC). CQDs facilitate the intracellular generation of reactive oxygen species (ROS), leading to glutathione depletion. These processes result in crucial actions such as the downregulation of glutathione peroxidase 4, downregulation of solute carrier family 7 member 11, and inhibition of cystine intake. The subsequent intracellular ROS, originating from lipid peroxidation, induces ferroptosis. Our HA-CQDs engage CD44 receptors, selectively targeting TNBCs and enhancing cancer recognition. This interaction potentially enhances the nanoplatform-based CD44 targeted therapeutic effects in inducing ferroptosis.
癌症治疗领域正在积极探索具有卓越性能的高效自靶向药物递送材料。最近,透明质酸(HA),一种天然存在的多糖,已被认为是CD44受体的潜在靶向配体,CD44受体在癌症治疗中所针对的各种实体瘤细胞上经常表达。HA碳量子点(CQDs)具有多种优势特性,包括高比表面积、小粒径、生物相容性和低细胞毒性,使其成为生物医学应用的理想选择,例如在基于铁死亡的癌症治疗中进行CD44靶向药物递送。在本研究中,我们合成了HA-CQDs,以增强针对三阴性乳腺癌(TNBC)的CD44介导的配体-受体相互作用。CQDs促进细胞内活性氧(ROS)的产生,导致谷胱甘肽耗竭。这些过程导致关键作用,如谷胱甘肽过氧化物酶4的下调、溶质载体家族7成员11的下调以及胱氨酸摄取的抑制。随后源自脂质过氧化的细胞内ROS诱导铁死亡。我们的HA-CQDs与CD44受体结合,选择性靶向TNBC并增强癌症识别。这种相互作用可能增强基于纳米平台的CD44靶向治疗在诱导铁死亡方面的效果。
ACS Appl Mater Interfaces. 2024-7-24
ACS Appl Mater Interfaces. 2021-1-13
Bioact Mater. 2023-11-15
Microsyst Nanoeng. 2023-11-17